Progressive massive fibrosis: Difference between revisions

Jump to navigation Jump to search
Shankar Kumar (talk | contribs)
No edit summary
Shankar Kumar (talk | contribs)
No edit summary
 
Line 13: Line 13:
==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{SIB}}
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 03:23, 25 September 2012

WikiDoc Resources for Progressive massive fibrosis

Articles

Most recent articles on Progressive massive fibrosis

Most cited articles on Progressive massive fibrosis

Review articles on Progressive massive fibrosis

Articles on Progressive massive fibrosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Progressive massive fibrosis

Images of Progressive massive fibrosis

Photos of Progressive massive fibrosis

Podcasts & MP3s on Progressive massive fibrosis

Videos on Progressive massive fibrosis

Evidence Based Medicine

Cochrane Collaboration on Progressive massive fibrosis

Bandolier on Progressive massive fibrosis

TRIP on Progressive massive fibrosis

Clinical Trials

Ongoing Trials on Progressive massive fibrosis at Clinical Trials.gov

Trial results on Progressive massive fibrosis

Clinical Trials on Progressive massive fibrosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Progressive massive fibrosis

NICE Guidance on Progressive massive fibrosis

NHS PRODIGY Guidance

FDA on Progressive massive fibrosis

CDC on Progressive massive fibrosis

Books

Books on Progressive massive fibrosis

News

Progressive massive fibrosis in the news

Be alerted to news on Progressive massive fibrosis

News trends on Progressive massive fibrosis

Commentary

Blogs on Progressive massive fibrosis

Definitions

Definitions of Progressive massive fibrosis

Patient Resources / Community

Patient resources on Progressive massive fibrosis

Discussion groups on Progressive massive fibrosis

Patient Handouts on Progressive massive fibrosis

Directions to Hospitals Treating Progressive massive fibrosis

Risk calculators and risk factors for Progressive massive fibrosis

Healthcare Provider Resources

Symptoms of Progressive massive fibrosis

Causes & Risk Factors for Progressive massive fibrosis

Diagnostic studies for Progressive massive fibrosis

Treatment of Progressive massive fibrosis

Continuing Medical Education (CME)

CME Programs on Progressive massive fibrosis

International

Progressive massive fibrosis en Espanol

Progressive massive fibrosis en Francais

Business

Progressive massive fibrosis in the Marketplace

Patents on Progressive massive fibrosis

Experimental / Informatics

List of terms related to Progressive massive fibrosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Complex pneumoconiosis

Overview

Progressive Massive Fibrosis is also known as Complex Pneumoconiosis. It is a disease that almost entirely affects coal miners. The disease arises firstly through the deposition of coal dust within the lung, and then through the body's immunological reactions to the dust. If disease is to be classified as PMF, the lung must contain lesions which are at least 1 cm in size, although some authorities place the boundary at 2 cm. In PMF, lesions most commonly occupy the upper lobes of the lung. Another characteristic of PMF lesions is that they are black.[1]. The pathogenesis of PMF is complicated, but involves two main routes - an immunological route, and a mechanical route.

Immunologically, disease is caused primarily through the activity of lung macrophages, which phagocytose dust particles after their deposition. These macrophages seek to eliminate the dust particle through either the mucociliary mechanism, or through lymphatic vessels which drain the lungs. Macrophages also produce an inflammatory mediator known as interleukin-1 (IL-1), which is part of the immune systems first line defenses against infecting particles. IL-1 is responsible for 'activation' of local vasculature, causing endothelial cells to express certain cell adhesion molecules, which help the cells of the bodies immune system to migrate into tissues. Macrophages exposed to dust have been shown to have markedly decreased chemotaxis. Production of inflammatory mediators - and the tissue damage that ensues as an effect of this, as well as reduced motility of cells, is fundamental to the pathogenesis of pneumoconiosis and the accompanying inflammation, fibrosis, and emphysema.

There are also some mechanical factors involved in the pathogenesis of Complex Pneumoconiosis that should be considered. The most notable indications are the fact that the disease tends to develop in the upper lobe of the lung - especially on the right, and its common occurrence in taller individuals.

References

Template:WH Template:WS Template:Jb1